Singh Virendra, Rastogi Neeraj, Mathur Neeraj, Singh Kalpana, Singh Mahendra Pratap
Industrial Toxicology Research Centre, Lucknow, India.
Ann Epidemiol. 2008 Jan;18(1):48-57. doi: 10.1016/j.annepidem.2007.06.006. Epub 2007 Aug 24.
Single nucleotide polymorphism (SNP) at position -309 (T309G) in MDM-2 promoter induces tumor formation in the individuals possessing inherited p53 mutations. The present study was undertaken to investigate the association of MDM-2 SNP309, p53 Arg72Pro, and p53 intron-6 G/A polymorphism with total, premenopausal, and postmenopausal breast cancer risks in Indian women.
Genotyping of MDM-2 SNP309, p53 Arg72Pro, and p53 intron-6 G/A in 104 patients and 105 controls was performed either by ARMS-PCR or by polymerase chain reaction and direct sequencing.
The p53 Arg72Pro heterozygous variant and in combination with its homozygous variant exhibited a significant protective association with total (odds ratio [95% confidence interval]: 0.42 [0.22-0.81] and 0.46 [0.25-0.85], p value; 0.007 and 0.012) and postmenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.25 [0.07-0.73] and 0.27 [0.08-0.77], p value; 0.009 and 0.013]. Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
The results indicate protective associations of p53 Arg72Pro heterozygous variant with postmenopausal and MDM-2 SNP309G along with p53 Arg72Pro heterozygous variant with premenopausal breast cancer risk.
MDM-2启动子区-309位(T309G)的单核苷酸多态性(SNP)可在携带遗传性p53突变的个体中诱发肿瘤形成。本研究旨在调查MDM-2 SNP309、p53 Arg72Pro和p53内含子6 G/A多态性与印度女性的总体、绝经前和绝经后乳腺癌风险之间的关联。
采用扩增阻滞突变系统聚合酶链反应(ARMS-PCR)或聚合酶链反应及直接测序法,对104例患者和105例对照进行MDM-2 SNP309、p53 Arg72Pro和p53内含子6 G/A基因分型。
p53 Arg72Pro杂合变异体及其纯合变异体组合与总体(比值比[95%置信区间]:0.42[0.22 - 0.81]和0.46[0.25 - 0.85],p值:0.007和0.012)以及绝经后乳腺癌风险呈现显著的保护关联(比值比[95%置信区间]:0.25[0.07 - 0.73]和0.27[0.08 - 0.77],p值:0.009和0.013)。单独的或纯合/杂合的MDM-2 SNP309G均与总体、绝经前或绝经后乳腺癌风险无关;然而,MDM-2 SNP309G与p53 Arg72Pro杂合变异体一起,与绝经前乳腺癌风险呈现显著的保护关联(比值比[95%置信区间]:0.18[0.02 - 1.20],p值:纯合 + 杂合MDM-2 SNP309G为0.041)。
结果表明p53 Arg72Pro杂合变异体与绝经后乳腺癌风险存在保护关联,MDM-2 SNP309G与p53 Arg72Pro杂合变异体一起与绝经前乳腺癌风险存在保护关联。